title: Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients.
abstract: OBJECTIVE
  The objective of this retrospective study was to determine the clinical outcomes of patients with primary fallopian tube carcinoma (PFTC) treated with paclitaxel and platinum analogue-based combination chemotherapy following primary cytoreductive surgery.
  
  
  METHODS
  Sixty-four patients with the diagnosis of PFTC were identified through the gynecology service database and the tumor registry of 4 different institutions. The majority of patients (48/64, 75%) were treated with carboplatin AUC (area under curve) 6 and paclitaxel 175 mg/m(2) as a 3 h infusion.
  
  
  RESULTS
  Among 28 patients with measurable disease, we observed 19 (68%) complete clinical and 7 (25%) partial responses for an overall response rate of 93%. After a median follow-up of 40 months (3+-134+ months), the 5-year survival rate of the entire population was 70% (median overall survival [mOS] not reached) and the median time to tumor progression (mTTP) was 81 months (95% CI: 53-109). Stage and residual disease were of prognostic significance. The mTTP was not reached in patients with stage I/II and was 38 months for patients with stage III/IV (p=0.004). The mOS for patients with stage I/II was not reached, whereas it was 62 months for those with stage III/IV (p=0.057). The mTTP was 86 and 23 months for patients with residual disease <2 cm and >2 cm, respectively (p<0.001). The mOS was not reached for patients with residual disease <2 cm, while it was 36 months for residual disease >2 cm (p<0.001).
  
  
  CONCLUSIONS
  Optimally cytoreduced patients with PFTC treated with platinum and paclitaxel-based chemotherapy regimen have an excellent possibility of survival.
authors.affiliation: 2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece.
authors.forename: D
authors.initials: D
authors.lastname: Pectasides
authors.affiliation: 2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece. Electronic address: pectasid@otenet.gr.
authors.forename: E
authors.initials: E
authors.lastname: Pectasides
authors.affiliation: 2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece.
authors.forename: G
authors.initials: G
authors.lastname: Papaxoinis
authors.affiliation: Department of Medical Oncology, Theagenion Cancer Hospital, Thessaloniki, Greece.
authors.forename: C
authors.initials: C
authors.lastname: Andreadis
authors.affiliation: 2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece.
authors.forename: G
authors.initials: G
authors.lastname: Papatsibas
authors.affiliation: Department of Medical Oncology, "Papageorgiou" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
authors.forename: G
authors.initials: G
authors.lastname: Fountzilas
authors.affiliation: 2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece.
authors.forename: K
authors.initials: K
authors.lastname: Pliarchopoulou
authors.affiliation: 3rd Department of Surgery, University of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Macheras
authors.affiliation: 3rd Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
authors.forename: G
authors.initials: G
authors.lastname: Aravantinos
authors.affiliation: 2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece.
authors.forename: T
authors.initials: T
authors.lastname: Economopoulos
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin